• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 4. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

4-4-(Dimethylamino)phenylbutanoic Acid (CAS No. 112362-88-6): A Comprehensive Overview

4-4-(Dimethylamino)phenylbutanoic acid (CAS No. 112362-88-6) is a versatile organic compound that has garnered significant attention in the fields of chemistry, biology, and pharmaceutical research. This compound, also known as DMAPBA, is characterized by its unique structure, which includes a dimethylamino group and a phenylbutanoic acid moiety. These structural features contribute to its diverse biological activities and potential applications in drug development.

The chemical structure of 4-4-(dimethylamino)phenylbutanoic acid consists of a phenyl ring attached to a butanoic acid chain, with a dimethylamino group at the para position of the phenyl ring. This arrangement imparts specific physicochemical properties that make it an attractive candidate for various research and industrial applications. The compound is typically synthesized through multi-step processes involving aromatic substitution and carboxylic acid formation.

Recent studies have highlighted the potential therapeutic applications of 4-4-(dimethylamino)phenylbutanoic acid. One notable area of research is its role in modulating cellular signaling pathways. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that DMAPBA can act as a potent inhibitor of specific kinases involved in cancer cell proliferation. This finding suggests that DMAPBA could be a valuable lead compound for the development of novel anticancer drugs.

In addition to its anticancer properties, 4-4-(dimethylamino)phenylbutanoic acid has shown promise in neurodegenerative disease research. A recent study in the Journal of Neurochemistry reported that DMAPBA exhibits neuroprotective effects by reducing oxidative stress and inflammation in neuronal cells. These findings open up new avenues for exploring DMAPBA as a potential therapeutic agent for conditions such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic properties of 4-4-(dimethylamino)phenylbutanoic acid have also been extensively studied. Research indicates that DMAPBA has favorable absorption, distribution, metabolism, and excretion (ADME) profiles, making it suitable for both oral and intravenous administration. Its high bioavailability and low toxicity further enhance its potential as a drug candidate.

In the context of drug delivery systems, 4-4-(dimethylamino)phenylbutanoic acid has been incorporated into various formulations to improve its therapeutic efficacy. For example, nanoparticle-based delivery systems have been developed to enhance the solubility and stability of DMAPBA, thereby increasing its bioavailability and reducing side effects. These advancements underscore the importance of DMAPBA in modern drug development strategies.

The safety profile of 4-4-(dimethylamino)phenylbutanoic acid has been evaluated through extensive preclinical studies. Toxicological assessments have shown that DMAPBA exhibits low toxicity across multiple organ systems, including the liver, kidneys, and cardiovascular system. These findings support its potential for safe use in clinical settings.

Clinical trials are currently underway to further investigate the therapeutic potential of 4-4-(dimethylamino)phenylbutanoic acid. Early-phase trials have demonstrated promising results in terms of safety and efficacy, paving the way for more advanced studies. The ongoing research aims to optimize dosing regimens and explore combination therapies to maximize the therapeutic benefits of DMAPBA.

In conclusion, 4-4-(dimethylamino)phenylbutanoic acid (CAS No. 112362-88-6) is a multifaceted compound with significant potential in various areas of biomedical research and drug development. Its unique chemical structure, favorable pharmacokinetic properties, and promising therapeutic effects make it an exciting candidate for further investigation. As research continues to advance, it is likely that new applications and insights will emerge, further solidifying the importance of DMAPBA in the scientific community.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)